WARRINGTON, Pa., May 13, 2015 /PRNewswire/ -- Discovery
Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology
company focused on developing aerosolized KL4 surfactant therapies
for respiratory diseases, will announce top-line results from its
AEROSURF® Phase 2a clinical trial in premature infants
29 – 34 gestational age with respiratory distress syndrome (RDS) on
Thursday, May 14, 2015 at
approximately 7:00 a.m. EDT.
Discovery Labs management will host a conference call and live
webcast, including a slide presentation, on Thursday, May 14, 2015 at 8:00 a.m. EDT to
review and discuss the results of the trial. The live webcast and
archive of the conference call can be accessed at
http://discoverylabs.investorroom.com/events.
For "listen-only" participants and those who wish to take part
in the question and answer portion of the call, dial (888) 346-0767
(domestic) or (412) 902-4251 (international). After placing the
call, request to be joined into the Discovery Labs conference
call. A replay of the conference call will be accessible one
hour after completion through May 22,
2015 by dialing (877) 344-7529 (domestic) or (412) 317-0088
(international) and referencing conference ID number 10065912.
About Discovery Labs
Discovery Laboratories, Inc. is a specialty biotechnology
company focused on developing aerosolized KL4 surfactant therapies
for respiratory diseases. Surfactants are produced naturally
in the lung and are essential for normal respiratory function and
survival. If surfactant deficiency or degradation occurs, the
air sacs in the lungs can collapse, resulting in severe respiratory
diseases and disorders. Discovery Labs' technology platform
includes a novel synthetic peptide-containing (KL4) surfactant,
that is structurally similar to pulmonary surfactant, and
proprietary drug delivery technologies being developed to enable
efficient delivery of aerosolized KL4 surfactant. Discovery
Labs believes that its proprietary technology platform makes it
possible, for the first time, to develop a significant pipeline of
aerosolized surfactant products to address a variety of respiratory
diseases for which there frequently are few or no approved
therapies.
For more information, please visit the Company's website at
www.Discoverylabs.com.
Forward-Looking Statements
To the extent that statements in this press release are not
strictly historical, all such statements are forward-looking, and
are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. These
forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially
from the statements made. Examples of such risks and
uncertainties are described in Discovery Labs' filings with the
Securities and Exchange Commission, including the most recent
reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto.
Except as otherwise required by law, Discovery Labs
undertakes no obligation to update or revise any forward-looking
statements.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/discovery-labs-to-announce-results-from-aerosurf-phase-2a-clinical-trial-300082681.html
SOURCE Discovery Laboratories, Inc.